When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Immunologists from the Institute have been the first to uncover a role for a family of RNA binding proteins in the function ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

CAR-T-cell therapies can be highly effective cancer treatments, but some recipients have reported long-term difficulties with ...

The future is bright for prostate cancer research. It's glowing, in fact, thanks to new tools that combine the eye-catching ...

Malcolm Brenner, M.D., Ph.D., Founding Director of the Center for Cell and Gene Therapy and Fayez Sarofim Distinguished Service Professor at Baylor College of Medicine in the Departments of Medicine, ...

Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, ...

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its ...

Cancer treatment with a cell-based immunotherapy causes mild cognitive impairment, a Stanford Medicine team found. They also identified compounds that could treat it.

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...